Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who previously took part in the INSIGHT cohort study
- People aged between 70 and 95 years old
- People who have signed a consent form agreeing to take part
- People who are willing and able to have a brain scan called a PET amyloid scan at the start of the study
- People who are covered by the French healthcare system
- People who have a family member, friend, or other contact person who knows them well enough to answer questions — at least by phone — about their thinking and day-to-day abilities
Who may not be able to join:
- People whose memory or thinking difficulties rate at a certain level of severity on a standard assessment scale used at the screening visit (confirm with trial site)
- People who, at the screening visit, meet the research diagnosis for any type of dementia, including Alzheimer's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, or several other related conditions
- People who have a medical condition known to be associated with a long-term risk of memory or thinking problems, such as Parkinson's disease, a brain tumour, a significant stroke, serious head injury with lasting effects, active alcohol or drug misuse, major depression, schizophrenia, or bipolar disorder
- People who have a serious or unstable illness affecting the heart, liver, kidneys, lungs, or blood, which the trial team considers could make participation unsafe
- People who cannot have an MRI or PET scan — for example, due to severe claustrophobia or having certain metal objects in their body — or who have a contraindication to the specific scan substances used in this trial
- People who have a known allergy or sensitivity to the scan substance used in this trial (18F-Florbetapir / Amyvid®) or any of its ingredients
- People who have taken part in a clinical trial of an investigational (unapproved) product in the 30 days before the screening visit
- People who the trial investigator believes would not be able to follow the study requirements
- People who are under a legal protection measure such as guardianship or curatorship
- People who live in a residential aged care or nursing home facility
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Stéphanie BOMBOIS, MD, Institut de la Mémoire et de la Maladie d'Alzheimer (IM2A)
Phone: +331 42 16 75 15
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The primary endpoint is the conversion to typical AD during the 5-year follow-up.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.